CAI vs. TLX
CAI (Caris Life Sciences, Inc) and TLX (Telix Pharmaceuticals Ltd) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, CAI returned -44.12% vs -24.21% for TLX. Their 0.14 correlation means their historical movements had little consistent relationship.
Performance
CAI vs. TLX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CAI achieves a -41.92% return, which is significantly lower than TLX's 32.04% return.
CAI
- 1D
- -2.61%
- 1M
- -14.37%
- 6M
- -32.34%
- YTD
- -41.92%
- 1Y
- -44.12%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -38.56%
TLX
- 1D
- -1.69%
- 1M
- -16.68%
- 6M
- 35.85%
- YTD
- 32.04%
- 1Y
- -24.21%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -24.51%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $56.64M | $58.13M | $55.03M | |
| $1.15M | $1.47M | $1.66M |
CAI vs. TLX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
CAI Caris Life Sciences, Inc | -41.92% | -0.07% |
TLX Telix Pharmaceuticals Ltd | 32.04% | -55.41% |
Correlation
The correlation between CAI and TLX is 0.13, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.13 |
Correlation (All Time) Calculated using the full available price history since Jun 18, 2025 | 0.14 |
Fundamentals
CAI:
$4.43B
TLX:
$3.35B
CAI:
$0.05
TLX:
A$0.12
CAI:
346.13
TLX:
121.72
CAI:
1.32
TLX:
0.15
CAI:
12.96
TLX:
2.39
CAI:
7.46
TLX:
7.66
CAI:
$907.29M
TLX:
A$2.00B
CAI:
$482.11M
TLX:
A$1.13B
CAI:
$92.24M
TLX:
A$153.71M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CAI vs. TLX — Risk / Return Rank
CAI
TLX
CAI vs. TLX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CAI | TLX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.26 | ||
| Sortino ratioReturn per unit of downside risk | -0.47 | ||
| Omega ratioGain probability vs. loss probability | 0.89 | 0.96 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | -0.70 | -0.53 | -0.18 |
| Martin ratioReturn relative to average drawdown | -1.05 | -0.90 | -0.15 |
Loading charts...
Drawdowns
CAI vs. TLX - Drawdown Comparison
The maximum CAI drawdown since its inception was -62.98%, smaller than the maximum TLX drawdown of -69.37%. Use the drawdown chart below to compare losses from any high point for CAI and TLX.
Loading charts...
Drawdown Indicators
| CAI | TLX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.98% | -69.37% | +6.39% |
Max Drawdown (1Y)Largest decline over 1 year | -62.98% | -51.88% | -11.10% |
Current DrawdownCurrent decline from peak | -60.13% | -52.75% | -7.38% |
Average DrawdownAverage peak-to-trough decline | -34.56% | -37.78% | +3.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.97% | 31.54% | +10.43% |
Volatility
CAI vs. TLX - Volatility Comparison
Caris Life Sciences, Inc (CAI) and Telix Pharmaceuticals Ltd (TLX) have volatilities of 12.19% and 12.52%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CAI | TLX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.19% | 12.52% | -0.33% |
Volatility (6M)Calculated over the trailing 6-month period | 48.04% | 40.47% | +7.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 60.78% | 57.69% | +3.09% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 61.20% | 56.39% | +4.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 61.20% | 56.39% | +4.81% |
Dividends
CAI vs. TLX - Dividend Comparison
Neither CAI nor TLX has paid dividends to shareholders.
Financials
CAI vs. TLX - Financials Comparison
This section allows you to compare key financial metrics between Caris Life Sciences, Inc and Telix Pharmaceuticals Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CAI vs. TLX - Profitability Comparison
CAI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Caris Life Sciences, Inc reported a gross profit of 0.00 and revenue of 216.17M. Therefore, the gross margin over that period was 0.0%.
TLX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Telix Pharmaceuticals Ltd reported a gross profit of 327.42M and revenue of 620.44M. Therefore, the gross margin over that period was 52.8%.
CAI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Caris Life Sciences, Inc reported an operating income of 5.28M and revenue of 216.17M, resulting in an operating margin of 2.4%.
TLX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Telix Pharmaceuticals Ltd reported an operating income of 9.82M and revenue of 620.44M, resulting in an operating margin of 1.6%.
CAI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Caris Life Sciences, Inc reported a net income of -510.00K and revenue of 216.17M, resulting in a net margin of -0.2%.
TLX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Telix Pharmaceuticals Ltd reported a net income of -7.25M and revenue of 620.44M, resulting in a net margin of -1.2%.
Frequently Asked Questions
CAI and TLX have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TLX has higher volatility (12.52%) compared to CAI (12.19%). In terms of maximum drawdown, CAI dropped -62.98% vs TLX's -69.37%.
TLX currently has the higher Sharpe Ratio (-0.47 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CAI and TLX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer